论文部分内容阅读
我国最新的糖尿病流行病学调查显示,在年龄≥20岁的中国人群中,糖尿病和糖尿病前期患病率分别为9.7%和15.5%。基于糖尿病所带来的巨大危害和沉重负担,遏制糖尿病在我国的蔓延已刻不容缓,糖尿病患者血糖的安全达标亦尤为重要。令人担忧的是,我国糖尿病患病率虽高,但血糖达标率却较低,并形成了巨大的反差。2006年中国地区的糖尿病现状调查显示,仅26.8%的患者血糖控制理想,糖化血红蛋白(HbA1c)≤6.5%;而73.2%的患者血糖控制未能达标(HbA1c>6.5%),HbA1c>8%的患者占28.3%。在目前所用的降糖药物中,胰岛素的疗效最为显著,更容易帮助患者血糖控制达标。并且,随着研发的深入开展和临床经验的积累,胰岛素治疗在剂型、使用策略以及注射装置等方面都大步迈进。胰岛素注射技术对血糖管理的影响已得到广泛的关注,第二次全球胰岛素注射技术现状调查相关数据显示,中国相当大比例的患者没有进行规范注射。
The latest epidemiological survey of diabetes in China shows that prevalence of diabetes and pre-diabetes are 9.7% and 15.5% respectively in the Chinese population ≥20 years of age. Based on the huge harm and heavy burden brought by diabetes, it is urgent to stop the spread of diabetes in our country. It is also very important to achieve the safety standard of blood glucose in diabetic patients. Worryingly, although the prevalence of diabetes in our country is high, but the blood sugar compliance rate is lower, and the formation of a huge contrast. In 2006, a survey of diabetes status in China showed that only 26.8% of patients had ideal glycemic control, with HbA1c ≤ 6.5%; 73.2% of patients had failed to achieve glycemic control (HbA1c> 6.5%), HbA1c> 8% Patients accounted for 28.3%. In the currently used hypoglycemic drugs, the most obvious effect of insulin, easier to help patients achieve glycemic control. And, with the deepening of research and development and the accumulation of clinical experience, insulin treatment strides forward in terms of dosage forms, usage strategies, and injection devices. The impact of insulin injections on glycemic control has received widespread attention. Relevant data from the Second Global Insulin Injection Technology Survey show that a significant proportion of patients in China are not given a standardized injection.